Atul Dandekar Sells 3,243 Shares of Maze Therapeutics (NASDAQ:MAZE) Stock

Maze Therapeutics, Inc. (NASDAQ:MAZE) insider Atul Dandekar sold 3,243 shares of the business’s stock in a transaction on Thursday, September 3rd. The shares were sold at an average price of $26.01, for a total transaction of $84,350.43. Following the completion of the transaction, the insider owned 32,316 shares in the company, valued at approximately $840,539.16. The trade was a 9.12% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Atul Dandekar also recently made the following trade(s):

• On Wednesday, September 2nd, Atul Dandekar sold 3,191 shares of Maze Therapeutics stock. The shares were sold at an average price of $26.47, for a total value of $84,465.77.
• On Friday, August 28th, Atul Dandekar sold 7,500 shares of Maze Therapeutics stock. The shares were sold at an average price of $27.58, for a total value of $206,850.00.
• On Wednesday, July 29th, Atul Dandekar sold 7,500 shares of Maze Therapeutics stock. The stock was sold at an average price of $27.34, for a total value of $205,050.00.
• On Monday, June 29th, Atul Dandekar sold 7,500 shares of Maze Therapeutics stock. The stock was sold at an average price of $28.02, for a total value of $210,150.00.

Maze Therapeutics Price Performance

Shares of MAZE opened at $26.21 on Friday. The firm has a market cap of $1.46 billion, a PE ratio of -10.40 and a beta of 2.17. Maze Therapeutics, Inc. has a 52-week low of $14.27 and a 52-week high of $53.65. The business’s 50 day moving average price is $28.69 and its two-hundred day moving average price is $31.17. The company has a debt-to-equity ratio of 0.09, a quick ratio of 18.31 and a current ratio of 18.31.

Maze Therapeutics (NASDAQ:MAZE) last announced its quarterly earnings data on Tuesday, August 11th. The company reported ($0.76) EPS for the quarter, hitting the consensus estimate of ($0.76). On average, equities analysts anticipate that Maze Therapeutics, Inc. will post -2.72 EPS for the current year.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in the business. Royal Bank of Canada increased its position in shares of Maze Therapeutics by 128.3% during the fourth quarter. Royal Bank of Canada now owns 646 shares of the company’s stock worth $27,000 after acquiring an additional 363 shares in the last quarter. Ameritas Investment Partners Inc. boosted its stake in Maze Therapeutics by 82.6% during the 3rd quarter. Ameritas Investment Partners Inc. now owns 1,632 shares of the company’s stock valued at $42,000 after purchasing an additional 738 shares during the last quarter. California State Teachers Retirement System increased its holdings in Maze Therapeutics by 138.0% during the 4th quarter. California State Teachers Retirement System now owns 1,321 shares of the company’s stock worth $55,000 after purchasing an additional 766 shares in the last quarter. Police & Firemen s Retirement System of New Jersey raised its stake in shares of Maze Therapeutics by 18.5% in the fourth quarter. Police & Firemen s Retirement System of New Jersey now owns 5,961 shares of the company’s stock worth $247,000 after purchasing an additional 931 shares during the last quarter. Finally, Legal & General Group Plc lifted its holdings in shares of Maze Therapeutics by 23.0% in the third quarter. Legal & General Group Plc now owns 5,219 shares of the company’s stock valued at $135,000 after purchasing an additional 977 shares in the last quarter.

More Maze Therapeutics News

Here are the key news stories impacting Maze Therapeutics this week:

• Positive Sentiment: Analyst sentiment remains broadly constructive. TD Cowen upgraded MAZE to “strong buy,” BTIG reiterated a “buy” rating with a $46 price target, and the consensus rating is “buy” with an average target of $66.00. Maze Therapeutics insider trading and analyst coverage
• Neutral Sentiment: Institutional ownership activity included purchases or position increases by Royal Bank of Canada, Russell Investments Group and other firms. These holdings are relatively small, however, and are unlikely to be a major near-term price driver.
• Neutral Sentiment: Maze’s CEO Jason Coloma, CMO Harold Bernstein and other insiders sold shares between September 1 and September 3. Combined reported sales totaled roughly $2.4 million, but the filings said the transactions were made to cover tax obligations from equity vesting; Bernstein’s September 1 sale was also conducted under a pre-arranged Rule 10b5-1 plan. SEC insider trading filing
• Negative Sentiment: The scale and repetition of insider selling may weigh on investor sentiment, particularly as the CEO reduced his directly held shares substantially. MAZE has also been trading below its 50-day and 200-day moving averages, signaling continued technical weakness. The company remains loss-making, with quarterly EPS of negative $0.76 and analysts expecting approximately negative $2.72 EPS for the year.

Wall Street Analyst Weigh In

MAZE has been the topic of several research reports. TD Cowen upgraded shares of Maze Therapeutics to a “strong-buy” rating in a report on Monday, August 24th. Wall Street Zen downgraded Maze Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, August 15th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Maze Therapeutics in a research report on Wednesday, June 24th. Finally, BTIG Research reaffirmed a “buy” rating and set a $46.00 price target on shares of Maze Therapeutics in a research note on Wednesday, August 12th. Three equities research analysts have rated the stock with a Strong Buy rating, eight have assigned a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Buy” and a consensus target price of $66.00.

About Maze Therapeutics

Maze Therapeutics, Inc (NASDAQ: MAZE) is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics by leveraging insights from human genetics and genomics. The company applies advanced data analytics and proprietary platforms to identify targets with strong genetic validation, aiming to de‐risk early drug discovery and accelerate the development of medicines for patients with serious diseases. Maze’s approach centers on translating naturally occurring human mutations into a deeper understanding of disease biology, with an emphasis on validating therapeutic hypotheses before advancing into the clinic.

Since its inception, Maze has assembled a diversified pipeline of programs across metabolic, immunological and other therapeutic areas.